
Bioxodes appoints Dr. Hans Warrinnier as Chief Medical Officer
November 02, 2021
Marche-en-Famenne, Belgium
To offer you a better experience, our website uses some cookies. To continue the visit, please accept our cookie policy
I agreeCookies information
Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:
These settings will be kept for 24h
Bioxodes takes advantage of its deep understanding of the thrombotic process to design drug candidates with an aim to achieve anticoagulation without hemorrhagic risk.
Our lead drug candidate, Ir-CPI, targets coagulation factors XIIa and XIa and prevents Neutrophil Extracellular Trap (NET) release, key driver components of the thrombo-inflammatory process.
In parallel, Bioxodes is developing a pipeline of drug candidates targeting chronic inflammatory diseases.
Our innovative pipeline includes a clinical-stage program with Ir-CPI for the prevention of acute thrombo-inflammatory processes. The initiation of the Phase IIa program to collect first evidence of efficacy in patients is expected early 2022.
With its unique mechanism of action on neutrophils and coagulation factors (FXIa and FXIIa), Ir-CPI displays an antithrombotic activity.
Bioxodes is building an innovative pipeline with drug candidates for the prevention of thrombo-inflammatory and inflammatory diseases.
Clinical trials are being conducted to assess the safety and efficacy of Ir-CPI in thrombo-inflammatory diseases.
Bioxodes appoints Dr. Hans Warrinnier as Chief Medical Officer
November 02, 2021
Marche-en-Famenne, Belgium
Bioxodes announces the completion of the active phase of its First-in-Human study performed in healthy adult volunteers with Ir-CPI
April 29, 2021
Marche-en-Famenne, Belgium
Bioxodes is a Belgian private company, founded in 2013. The Company has received fundings from both the public and private investors.
All investors